Toshiba Appoints Rance M. Poehler as President & Chief Executive Officer for Retail Solutions Business
16.11.2020 19:00:00 EET | Business Wire | Press release
Toshiba Global Commerce Solutions today announced Rance M. Poehler is joining the company as its new President and Chief Executive Officer effective November 16, 2020. Poehler has more than 25 years of experience building and expanding business-to-business organizations in unique vertical markets including retail where he has led the development of end-to-end solutions for general retail, quick-service restaurant, hospitality, and other segments. In his role, he will be responsible for leading the company’s continued transformation as a trusted retail commerce solutions leader for its large and growing customer and partner community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005083/en/
Rance M. Poehle, President & CEO, Toshiba Global Commerce Solutions (Photo: Business Wire)
Poehler replaces Scott Maccabe who had been appointed President & CEO since 2015. Maccabe is retiring from his role as President & CEO at Toshiba Global Commerce Solutions, while he remains in this capacity at Toshiba America Business Solutions. Poehler takes over effective immediately and will work closely with Maccabe to ensure a full and seamless transition of duties. We thank Scott Maccabe for his commitment, strong leadership and many contributions to the success and growth of the business.
“Rance Poehler is a highly accomplished business executive with a proven track-record for scaling businesses that are in a unique position to transform the industries they serve,” said Maccabe. “Rance brings the fortitude and execution prowess needed to transition the retail business to a full-fledged strategic partner for both customers and partners.”
Poehler joins Toshiba with extensive retail commerce solutions experience and insight. During his tenure as President of Panasonic Systems Communications Company of North America he led a $1.1 billion division morphing it from a product-centric organization to an end-to-end provider of innovative retail solutions in the areas of mobility, point-of-sale, digital signage, computer vision, and analytics that helped Fortune 1000 companies understand shopper demographics and behavior, improve associate engagement and create better customer experiences. While at Dell Technologies he served as vice president of worldwide sales for its cloud client computing team that represents a full suite of cloud and desktop virtualization solutions for retail that enabled scalable thin client solutions. Poehler’s experience also includes Pivot3 where he served as Chief Revenue Officer responsible for leading the global sales organization and executing on the company’s growth strategy and talent acquisition as they developed and went to market with a hyper-converged software platform that manages mixed workloads including IOT-surveillance, analytics, and hybrid cloud solutions.
“The retail industry is looking for new and innovative ways to adapt more quickly to customer needs while they optimize store operations and reduce the cost of delivering and managing their business. Toshiba has a strong worldwide retail position and is on the verge of disrupting the industry with their intelligent end-to-end solutions,” said Poehler. “I’m honored and excited about the opportunity to help this world-class retail commerce solutions business grow in ways that support our partner community, and helps our clients delight their customers while becoming even greater merchants.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for integrated in-store solutions. Together with a global team of dedicated business partners, we achieve brilliant commerce by advancing the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter, LinkedIn, Facebook and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005083/en/
Contact information
Fredrik Carlegren
Vice President of Marketing
(984) 444-2769
fcarlegren@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release
TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom